AHS 2023 | Biomarker-driven clinical trials and drug discovery in migraine

Yohannes Woldeamanuel, MD, Stanford University, Stanford, CA, comments on the potential clinical implications and applications of the candidate biomarker signatures identified in a recent proteomic study in migraine patients. The diagnosis and subclassification of migraine heavily relies on self-reported symptoms. The inaccurate reporting by patients and inadequate interviewing by clinicians can lead to misdiagnosis and subsequent mistreatment. The availability of biomarkers, especially serum biomarkers that can quickly be measured, can support and validate the diagnosis of migraine and predict the conversion of episodic migraine to chronic migraine. Importantly, these biomarkers can also be used in clinical trials to have a clear phenotype of the patients enrolled in the study. Biomarkers can also improve our understanding of pathological pathways and help discover and develop new treatments. This interview took place at the American Headache Society 2023 meeting in Austin, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.